Reata Pharmaceuticals, which is developing protein-based antioxidant inflammation modulators (AIMs) for life-threatening diseases, filed on Monday with the SEC to raise up to $80 million in an initial public offering.
The Irving, TX-based company, which was founded in 2002 and booked $51 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol RETA. Reata Pharmaceuticals filed confidentially on 10/19/2015. Citi, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
